VMD-928
VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma[1][2].
Product Specifications
CAS Number
1802770-18-8
UNSPSC
12352005
Target
Trk Receptor
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(C1=CC=C(NC(C=C(N2CCN(C3CCCCC3)CC2)C(N)=C4C(C5=C6C=CC=C5)=O)=C4C6=O)C=C1)O
Molecular Formula
C31H32N4O4
Molecular Weight
524.61
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ACCN2 Polyclonal Antibody, APC-Cy7 Conjugated
Recombinant Shigella Flexneri hnr Protein (aa 1-337)
Ccdc116 (NM_029779) Mouse Tagged ORF Clone Lentiviral Particle